{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T01:18:47Z","timestamp":1792718327570,"version":"4.5.0"},"reference-count":41,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,7]],"date-time":"2022-11-07T00:00:00Z","timestamp":1667779200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017636","name":"Pfizer Inc Centers for Therapeutic Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017636","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","jaad.org","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Dermatology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.jaad.2022.11.005","type":"journal-article","created":{"date-parts":[[2022,11,9]],"date-time":"2022-11-09T11:20:31Z","timestamp":1667992831000},"page":"395-403","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":159,"title":["Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial"],"prefix":"10.1016","volume":"88","author":[{"given":"Khaled","family":"Ezzedine","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Peeva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lori Ann","family":"Cox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anindita","family":"Banerjee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iltefat","family":"Hamzavi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anand K.","family":"Ganesan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Picardo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Diamant","family":"Tha\u00e7i","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John E.","family":"Harris","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jung Min","family":"Bae","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsuhiko","family":"Tsukamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rodney","family":"Sinclair","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit G.","family":"Pandya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abigail","family":"Sloan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dahong","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kavita","family":"Gandhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Vincent","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett","family":"King","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaad.2022.11.005_bib1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1159\/000506103","article-title":"Vitiligo: a review","volume":"236","author":"Bergqvist","year":"2020","journal-title":"Dermatology"},{"key":"10.1016\/j.jaad.2022.11.005_bib2","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1111\/j.1365-4632.2011.05377.x","article-title":"A review of the worldwide prevalence of vitiligo in children\/adolescents and adults","volume":"51","author":"Kruger","year":"2012","journal-title":"Int J Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib3","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.det.2016.11.002","article-title":"Quality of life, burden of disease, co-morbidities, and systemic effects in vitiligo patients","volume":"35","author":"Elbuluk","year":"2017","journal-title":"Dermatol Clin"},{"key":"10.1016\/j.jaad.2022.11.005_bib4","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1001\/jamadermatol.2021.4724","article-title":"Prevalence of vitiligo among adults in the United States","volume":"158","author":"Gandhi","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib5","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1111\/j.1755-148X.2012.00997.x","article-title":"Revised classification\/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference","volume":"25","author":"Ezzedine","year":"2012","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2022.11.005_bib6","doi-asserted-by":"crossref","first-page":"15011","DOI":"10.1038\/nrdp.2015.11","article-title":"Vitiligo","volume":"1","author":"Picardo","year":"2015","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.jaad.2022.11.005_bib7","first-page":"160","article-title":"Clinical practice. Vitiligo","volume":"360","author":"Taieb","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2022.11.005_bib8","first-page":"1717","article-title":"Vitiligo","volume":"2008","author":"Matin","year":"2008","journal-title":"BMJ Clin Evid"},{"key":"10.1016\/j.jaad.2022.11.005_bib9","doi-asserted-by":"crossref","first-page":"a017046","DOI":"10.1101\/cshperspect.a017046","article-title":"Melanocytes and their diseases","volume":"4","author":"Yamaguchi","year":"2014","journal-title":"Cold Spring Harb Perspect Med"},{"key":"10.1016\/j.jaad.2022.11.005_bib10","doi-asserted-by":"crossref","first-page":"778","DOI":"10.1111\/pcmr.12878","article-title":"The enigma and challenges of vitiligo pathophysiology and treatment","volume":"33","author":"Abdel-Malek","year":"2020","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2022.11.005_bib11","doi-asserted-by":"crossref","first-page":"408","DOI":"10.7861\/clinmedicine.9-5-408","article-title":"Vitiligo: what general physicians need to know","volume":"9","author":"Gawkrodger","year":"2009","journal-title":"Clin Med (Lond)"},{"key":"10.1016\/j.jaad.2022.11.005_bib12","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s13555-020-00447-y","article-title":"Vitiligo, from physiopathology to emerging treatments: a review","volume":"10","author":"Migayron","year":"2020","journal-title":"Dermatol Ther (Heidelb)"},{"key":"10.1016\/j.jaad.2022.11.005_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1001\/jamadermatol.2017.0002","article-title":"Phototherapy for vitiligo: a systematic review and meta-analysis","volume":"153","author":"Bae","year":"2017","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib14","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.immuni.2017.01.009","article-title":"CD49a expression defines tissue-resident CD8(+) t cells poised for cytotoxic function in human skin","volume":"46","author":"Cheuk","year":"2017","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2022.11.005_bib15","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aam7710","article-title":"Antibody blockade of IL-15 signaling has the potential to durably reverse vitiligo","volume":"10","author":"Richmond","year":"2018","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.jaad.2022.11.005_bib16","doi-asserted-by":"crossref","first-page":"3552","DOI":"10.3390\/ijms21103552","article-title":"The role of TRM cells in the pathogenesis of vitiligo-A review of the current state-of-the-art","volume":"21","author":"Fraczek","year":"2020","journal-title":"Int J Mol Sci"},{"key":"10.1016\/j.jaad.2022.11.005_bib17","doi-asserted-by":"crossref","first-page":"790125","DOI":"10.3389\/fimmu.2021.790125","article-title":"Janus kinase inhibitors in the treatment of vitiligo: a review","volume":"12","author":"Qi","year":"2021","journal-title":"Front Immunol"},{"key":"10.1016\/j.jaad.2022.11.005_bib18","doi-asserted-by":"crossref","first-page":"102842","DOI":"10.1016\/j.isci.2021.102842","article-title":"Targeting ITK signaling for T cell-mediated diseases","volume":"24","author":"Weeks","year":"2021","journal-title":"iScience"},{"key":"10.1016\/j.jaad.2022.11.005_bib19","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1056\/NEJMoa2019380","article-title":"Abrocitinib versus placebo or dupilumab for atopic dermatitis","volume":"384","author":"Bieber","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jaad.2022.11.005_bib20","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1001\/jamadermatol.2021.3023","article-title":"Efficacy and safety of upadacitinib vs dupilumab in adults with moderate-to-severe atopic dermatitis: a randomized clinical trial","volume":"157","author":"Blauvelt","year":"2021","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib21","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1111\/bjd.18898","article-title":"Baricitinib in patients with moderate-to-severe atopic dermatitis and inadequate response to topical corticosteroids: results from two randomized monotherapy phase III trials","volume":"183","author":"Simpson","year":"2020","journal-title":"Br J Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib22","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1016\/j.jaad.2016.12.005","article-title":"JAK inhibitors in dermatology: the promise of a new drug class","volume":"76","author":"Damsky","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib23","first-page":"15","article-title":"Selective JAKinibs: prospects in inflammatory and autoimmune diseases","volume":"33","author":"Virtanen","year":"2019","journal-title":"Bio Drugs"},{"key":"10.1016\/j.jaad.2022.11.005_bib24","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1038\/nrd.2017.201","article-title":"JAK inhibition as a therapeutic strategy for immune and inflammatory diseases","volume":"16","author":"Schwartz","year":"2017","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.jaad.2022.11.005_bib25","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1021\/acschembio.9b00188","article-title":"PF-06651600, a dual JAK3\/TEC family kinase inhibitor","volume":"14","author":"Xu","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.jaad.2022.11.005_bib26","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.jaad.2021.03.050","article-title":"A phase 2a randomized, placebo-controlled study to evaluate the efficacy and safety of the oral Janus kinase inhibitors ritlecitinib and brepocitinib in alopecia areata: 24-week results","volume":"85","author":"King","year":"2021","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib27","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1002\/art.41316","article-title":"Efficacy and safety of PF-06651600 (ritlecitinib), a novel JAK3\/TEC inhibitor, in patients with moderate-to-severe rheumatoid arthritis and an inadequate response to methotrexate","volume":"72","author":"Robinson","year":"2020","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib28","doi-asserted-by":"crossref","first-page":"S030","DOI":"10.1093\/ecco-jcc\/jjab075.032","article-title":"OP33 oral ritlecitinib and brepocitinib in patients with moderate to severe active ulcerative colitis: data from the VIBRATO umbrella study","volume":"15","author":"Sandborn","year":"2021","journal-title":"J Crohn's Colitis"},{"key":"10.1016\/j.jaad.2022.11.005_bib29","series-title":"CDER Patient-Focused Drug Development","year":"2021"},{"key":"10.1016\/j.jaad.2022.11.005_bib30","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/j.immuni.2021.08.019","article-title":"Resident memory CD8(+) T cells in regional lymph nodes mediate immunity to metastatic melanoma","volume":"54","author":"Molodtsov","year":"2021","journal-title":"Immunity"},{"key":"10.1016\/j.jaad.2022.11.005_bib31","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1111\/pcmr.12949","article-title":"An update on vitiligo pathogenesis","volume":"34","author":"Seneschal","year":"2021","journal-title":"Pigment Cell Melanoma Res"},{"key":"10.1016\/j.jaad.2022.11.005_bib32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.4049\/jimmunol.1900027","article-title":"The role of memory CD8(+) T cells in vitiligo","volume":"203","author":"Riding","year":"2019","journal-title":"J Immunol"},{"key":"10.1016\/j.jaad.2022.11.005_bib33","doi-asserted-by":"crossref","first-page":"1110","DOI":"10.1001\/jamadermatol.2015.1520","article-title":"Tofacitinib citrate for the treatment of vitiligo: a pathogenesis-Directed therapy","volume":"151","author":"Craiglow","year":"2015","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib34","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1001\/jamadermatol.2017.5778","article-title":"Rapid repigmentation of vitiligo using tofacitinib plus Low-dose, narrowband UV-B phototherapy","volume":"154","author":"Kim","year":"2018","journal-title":"JAMA Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib35","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jaad.2017.05.043","article-title":"Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure","volume":"77","author":"Liu","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib36","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jaad.2015.09.073","article-title":"Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA)","volume":"74","author":"Harris","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib37","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0140-6736(20)30609-7","article-title":"Ruxolitinib cream for treatment of vitiligo: a randomised, controlled, phase 2 trial","volume":"396","author":"Rosmarin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.jaad.2022.11.005_bib38","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3310\/hta24640","article-title":"Home-based narrowband UVB, topical corticosteroid or combination for children and adults with vitiligo: HI-Light vitiligo three-arm RCT","volume":"24","author":"Batchelor","year":"2020","journal-title":"Health Technol Assess"},{"key":"10.1016\/j.jaad.2022.11.005_bib39","doi-asserted-by":"crossref","first-page":"AB105","DOI":"10.1016\/j.jaad.2022.06.454","article-title":"Ritlecitinib (PF-06651600), an oral JAK3\/TEC inhibitor, stabilizes active lesions and promotes repigmentation of stable lesions in patients with active nonsegmental vitiligo: results from a phase 2b, randomized, placebo-controlled, dose-ranging study","volume":"87","author":"Yamaguchi","year":"2022","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib40","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s40257-017-0298-5","article-title":"Vitiligo: an update on pathophysiology and treatment options","volume":"18","author":"Speeckaert","year":"2017","journal-title":"Am J Clin Dermatol"},{"key":"10.1016\/j.jaad.2022.11.005_bib41","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/dth.12143","article-title":"Vitiligo nonsurgical treatment: a review of latest treatment researches","volume":"27","author":"Zhang","year":"2014","journal-title":"Dermatol Ther"}],"updated-by":[{"DOI":"10.1016\/j.jaad.2023.04.001","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2023,9,1]],"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000}}],"container-title":["Journal of the American Academy of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222029899?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0190962222029899?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T01:59:01Z","timestamp":1693101541000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0190962222029899"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":41,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,2]]}},"alternative-id":["S0190962222029899"],"URL":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.005","relation":{},"ISSN":["0190-9622"],"issn-type":[{"value":"0190-9622","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy and safety of oral ritlecitinib for the treatment of active nonsegmental vitiligo: A randomized phase 2b clinical trial","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Dermatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaad.2022.11.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Published by Elsevier on behalf of the American Academy of Dermatology, Inc.","name":"copyright","label":"Copyright"}]}}